These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 22376227)

  • 1. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
    Singh JA; Cameron DR
    J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.
    Kemper AR; Van Mater HA; Coeytaux RR; Williams JW; Sanders GD
    BMC Pediatr; 2012 Mar; 12():29. PubMed ID: 22420649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.
    Oderda GM; Balfe LM
    J Manag Care Pharm; 2011; 17(9 Suppl B):S19-24. PubMed ID: 22073936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
    Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
    J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial.
    Burrone M; Mazzoni M; Naddei R; Pistorio A; Spelta M; Scala S; Patrone E; Garrone M; Lombardi M; Villa L; Pascale G; Cavanna R; Ruperto N; Ravelli A; Consolaro A;
    Pediatr Rheumatol Online J; 2022 Sep; 20(1):80. PubMed ID: 36071444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
    Brunner HI; Wong R; Nys M; Kou TD; Dominique A; Martini A; Lovell DJ; Ruperto N;
    Paediatr Drugs; 2020 Dec; 22(6):653-672. PubMed ID: 33029724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
    Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative safety and effectiveness of TNF-alpha antagonists [corrected].
    Solomon DH
    J Manag Care Pharm; 2007 Jan; 13(1 Suppl):S7-18. PubMed ID: 17378700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.
    Grazziotin LR; Currie G; Twilt M; Ijzerman MJ; Kip MMA; Koffijberg H; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung RSM; Marshall DA
    Pediatr Rheumatol Online J; 2022 Apr; 20(1):25. PubMed ID: 35410419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of non-systemic juvenile idiopathic arthritis.
    Shenoi S; Horneff G; Aggarwal A; Ravelli A
    Nat Rev Rheumatol; 2024 Mar; 20(3):170-181. PubMed ID: 38321298
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.